1 2

Comprehensive multiomic profiling of somatic mutations in malformations of cortical development

3

Changuk Chung ^{1,2,#}, Xiaoxu Yang ^{1,2,#}, Taejeong Bae ³, Keng Ioi Vong ^{1,2}, Swapnil Mittal ^{1,2}, Catharina Donkels ⁴, H. Westley Phillips ⁵, Ashley P. L. Marsh ^{1,2}, Martin W. Breuss ^{1,2,6}, Laurel 4 5 L. Ball^{1,2}, Camila Araújo Bernardino Garcia⁷, Renee D. George^{1,2}, Jing Gu^{1,2}, Mingchu Xu^{1,2}, 6 Chelsea Barrows^{1,2}, Kiely N. James^{1,2}, Valentina Stanley^{1,2}, Anna Nidhiry^{1,2}, Sami Khoury^{1,2}, 7 Gabrielle Howe^{1,2}, Emily Riley^{1,2}, Xin Xu^{1,2}, Brett Copeland^{1,2}, Yifan Wang³, Se Hoon Kim⁸, 8 Hoon-Chul Kang⁸, Andreas Schulze-Bonhage⁹, Carola A. Haas^{4,9}, Horst Urbach¹⁰, Marco 9 Prinz ^{9,11}, Corrine Gardner ¹², Christina A. Gurnett ¹², Shifteh Sattar ¹³, Mark Nespeca ¹³, David 10 D. Gonda¹³, Katsumi Imai¹⁴, Yukitoshi Takahashi¹⁴, Robert Chen¹⁵, Jin-Wu Tsai¹⁵, Valerio 11 Conti¹⁶, Renzo Guerrini¹⁶, Orrin Devinsky¹⁷, Wilson A. Silva Jr¹⁸, Helio R. Machado⁷, Gary 12 W. Mathern ⁵, Alexej Abyzov ³, Sara Baldassari ¹⁹, St éphanie Boulac ¹⁹, Focal Cortical 13 Dysplasia Neurogenetics Consortium [&], Brain Somatic Mosaicism Network ^{*} and Joseph G. 14 Gleeson^{1,2,*} 15 16 17 ¹Department of Neurosciences, University of California San Diego, La Jolla, CA, 92037, USA 18 ²Rady Children's Institute for Genomic Medicine, San Diego, CA, 92123, USA 19 ³Department of Quantitative Health Sciences, Center for Individualized Medicine, Mayo Clinic, Mayo 20 Clinic, Rochester, MN, 55905, USA 21 ⁴Department of Neurosurgery, Experimental Epilepsy Research, Medical Center-University of Freiburg, 22 Faculty of Medicine, 79106 Freiburg, Germany ⁵Department of Neurosurgery, University of California at Los Angeles, CA, 90095, USA 23 24 ⁶Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado Aurora, 25 CO, 80045, USA ⁷Laboratory of Pediatric Neurosurgery and Developmental Neuropathology, Dept. of Surgery and 26 27 Anatomy, University of S ão Paulo (USP), Ribeir ão Preto, 14000-000, Brazil ⁸Div Pediatric Neurology, Dept of Pediatrics, Severance Children's Hospital, Yonsei U College of 28 29 Medicine, Seoul, Korea 30 ⁹Center for Basics in NeuroModulation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, 31 Germany 32 ¹⁰Department of Neuroradiology, Medical Center-University of Freiburg, Faculty of Medicine, 79106 33 Freiburg, Germany 34 ¹¹Institute of Neuropathology, Medical Center-University of Freiburg, Faculty of Medicine, 79106 35 Freiburg, Germany ¹²St. Louis Children's Hospital, Washington University St Louis, MO, 63110, USA 36 37 ¹³Epilepsy Center, Rady Children's Hospital, San Diego, CA, 92123, USA 38 ¹⁴National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka 420-39 8688. Japan 40 ¹⁵Institute of Brain Science, National Yang-Ming University, Beitou 112, Taipei, Taiwan 41 ¹⁶Paediatric Neurology Unit and Laboratories, A. Meyer Children's Hospital, University of Florence, Italy ¹⁷Epilepsy Service, Dept. Neurology, New York University, NY, 10016, USA 42 43 ¹⁸Department of Genetics, Center for Cell-Based Therapy, Center for Integrative Systems Biology, 44 University of S ão Paulo (USP), Ribeir ão Preto, 14000-000, Brazil 45 ¹⁹Paris Brain Institute - Institut du Cerveau - ICM, Hôpital Piti é Salp êtri ète - 47, bd de l'hôpital - 75013 46 Paris France 47 [#]These authors contributed equally

48 *Correspondence to: jogleeson@health.ucsd.edu

- 49 &Full membership of the FCD Neurogenetic Consortium is listed in the Supplement
- 50 *Full membership of the Brain Somatic Mosaicism Network is listed in the Supplement
- 51 Number of figures: 6, Number of extended data items: 7
- 52
- 53 Emails: chchung@health.ucsd.edu, xiy010@health.ucsd.edu, bae.taejeong@mayo.edu,
- 54 kivong@health.ucsd.edu, swmittal@ucsd.edu, catharina.donkels@uniklinik-freiburg.de,
- 55 carola.haas@uniklinik-freiburg.de, hphillips@mednet.ucla.edu, amarsh@health.ucsd.edu,
- 56 martin.breuss@cuanschutz.edu, llball@health.ucsd.edu, camila.neurociencias@gmail.com,
- 57 reneegeorge@gmail.com, j3gu@ucsd.edu, mxu.china@gmail.com, cbarrows@ucsd.edu,
- 58 kiely.n.james@gmail.com, vstanley146@gmail.com, anidhiry@gmail.com,
- 59 samikhoury619@gmail.com, ghowe@ucsd.edu, eariley@ucsd.edu, virginiaxuxin@gmail.com,
- 60 <u>brcopeland@gmail.com</u>, <u>paxco@yuhs.ac</u>, <u>hipo0207@yuhs.ac</u>, <u>andreas.schulze-</u>
- 61 <u>bonhage@uniklinik-freiburg.de</u>, <u>carola.haas@uniklinik-freiburg.de</u>, <u>gardnerc@wustl.edu</u>,
- 62 gurnettc@wustl.edu, ssattar@ucsd.edu, mnespeca@ucsd.edu, dgonda@rchsd.org, takahashi-
- 63 ped@umin.ac.jp, roberthhchen3@gmail.com, jinwu.tsai@gmail.com, valerio.conti@meyer.it,
- 64 renzo.guerrini@meyer.it, wilsonjr@usp.br, od4@nyu.edu, hrmachad@fmrp.usp.br,
- 65 gmathern@ucla.edu, jogleeson@health.ucsd.edu
- 66

Abstract: 129 words, Manuscript: 3101 words, Figures: 6, Extended Data items: 7, Suppl Tables: 3

- 69 Keywords: epilepsy, focal cortical dysplasia, brain mosaicism, mTOR, single-cell
- 70 sequencing, whole exome sequencing
- 71

72 Abstract

- 73 Malformations of cortical development (MCD) are neurological conditions displaying focal
- 74 disruption of cortical architecture and cellular organization arising during embryogenesis, largely
- from somatic mosaic mutations. Identifying the genetic causes of MCD has been a challenge, as
- 76 mutations remain at low allelic fractions in brain tissue resected to treat epilepsy. Here, we report
- a genetic atlas from 317 brain resections, identifying 69 mutated genes through intensive
- 78 profiling of somatic mutations, combining whole-exome and targeted-amplicon sequencing with
- 79 functional validation and single-cell sequencing. Genotype-phenotype correlation analysis
- 80 elucidated specific MCD gene sets associating distinct pathophysiological and clinical
- 81 phenotypes. The unique spatiotemporal expression patterns identified by comparing single-
- 82 nucleus transcriptional sequences of mutated genes in control and patient brains implicates
- critical roles in excitatory neurogenic pools during brain development, and in promoting
- 84 neuronal hyperexcitability after birth.
- 85

86 Introduction

- 87 MCDs are heterogeneous groups of neurodevelopmental disorders with localized malformation
- of cortical structures, often presenting with intractable epilepsy¹. Major MCD subtypes include
- different classes of focal cortical dysplasia (FCD), hemimegalencephaly (HME), and tuberous
- 90 sclerosis complex (TSC)². The International League Against Epilepsy (ILAE) has classified FCD
- subtypes based upon neuropathological features and cell types³. MCD patients are often undergo

surgical resection of the lesion to treat drug-refractory epilepsy, which has led to remarkable

93 clinical benefit in published series⁴. The abnormal histology of resected regions includes loss of

- lamination of cortical layers, enlarged dysplastic neurons or balloon cells, sometimes
- accompanied by other brain abnormalities. But similar to brain tumors, it can be difficult to
 predict pathology prior to surgery.
- 97 Again, like with brain tumors, genetic studies may offer insights into mechanisms.
- 98 Somatic mTOR pathway gene mutations are frequently detected in HME and type II FCD foci^{5,6}.
- 99 Recently, small- or medium-size cohort studies (<100 cases) have confirmed these results and
- have correlated defects in neuronal migration, cell size and neurophysiology⁷. Still, the vast
- 101 majority of MCD cases still remain genetically unsolved, suggesting other genes or modules 102 contribute to MCD.
- 103 Detecting mutant alleles in bulk resected foci from MCD patients is challenging because 104 unlike in brain tumors, the mutant cells in MCD are probably not hyperproliferative, and thus
- 105 variant allelic fraction (VAF) are often <5%, diluted by genomes of surrounding non-mutated
- 106 cells⁸. Fortunately, new computational algorithms have helped reduce false-positive and false-
- 107 negative signals, even when no 'normal' paired sample is available for comparison⁹⁻¹¹. The NIH-
- 108 supported Brain Somatic Mosaicism Network established the 'BSMN common pipeline',
- 109 incorporating a 'best practice' workflow to reliably and reproducibly identify somatic variants
- 110 contributed by members of the Network 12 . With these advances, we thus assessed the possibility
- 111 of gene networks beyond mTOR that could underlie MCDs. This new gene discovery may give
- 112 insights on novel druggable pathways in cases of incomplete resection due to regional
- 113 importance or drug-resistant forms of MCD.
- 114

115 **Results**

116 The genetic landscape of MCD from targeted and unbiased sequencing

- 117 To perform a thorough genetic screening of somatic mutations in resected epileptic tissue, we 118 formed the FCD Neurogenetics Consortium and enrolled 327 samples that met clinical and
- 119 pathological criteria for FCD or HME. We excluded TSC from our enrollment criteria because
- 120 genes are already well known. Our cohort included 31 HME cases, 98 type I-, 142 type II-, 32
- type III-, and 12 unclassified-FCD cases. We included acute resected brain from 10
- neurotypicals and 2 TSC cases for comparison (Fig. 1a, supplementary table 1). Patients with
- environmental causes, syndromic presentations, inherited mutations, multifocal lesions, or
- 124 tumors were excluded (Methods).
- We used a three-phase genetic screening, each followed by filtering for likely causative
 mutations using published methods^{13,14}, and each followed by orthogonal targeted amplicon
 sequencing (TASeq) intra-case validation and VAF quantification compared with controls
 (~5000 X, TASeq)(Fig. 1b). In Phase 1, we performed amplicon sequencing (AmpliSeq, ~1000
 X) profiling the entire open reading frame of 87 genes previously detected in FCD/HMEs or
 known PI3K-AKT3-mTOR interactors ('MCD panel v1', Supplementary Table 2a). In Phase 2,
- for 75 unsolved cases from Phase 1 and additionally collected 54 cases, we performed unbiased
- deep whole-exome sequencing (WES, ~300 X) on paired samples, where available, or on
- 133 unpaired samples (i.e. brain plus blood/saliva vs. brain only). In Phase 3, from an additional
- 134 subcohort of 132 new cases, we designed the 'MCD panel v2' (Supplementary Table 2b)
- including known and novel genes detected in Phases 1 and 2 (Extended Data Fig. 1, Methods).
- 136 We re-sequenced unsolved cases from Phase 2, expecting that the higher read depth afforded by

panel sequencing could provided greater sensitivity to detect low VAF mutations, and used
 BSMN best practice guidelines for mapping and variant calling¹².

139From Phases 1 to 3, 1181 candidate somatic SNVs were identified. Of these, 628 were

- 140 excluded based on gnomAD allele frequencies, dinucleotide repeats, homopolymers, and
- 141 additional BSMN established criteria (Methods)^{15,16}. This yielded 554 candidate somatic SNV
- 142 that were further assessed by TASeq, yielding 108 validated somatic SNV calls (19.4%
- 143 validation rate, Fig. 1c, Supplementary Table 3), similar to other BSMN effort validation rates
- ^{12,17}. In detail, 15, 67 and 26 validated somatic SNV calls were derivated from phase1, 2 and
- 145 phase 3, respectively. The measured VAFs between the AmpliSeq/WES and TASeq were
- 146 correlated as expected ($R^2 = 0.7243$) (Fig. 1d). Of the 69 candidate MCD genes mutated in 76
- patients, 8 were recurrently mutated, including known mTOR pathway genes as well as severalnovel candidates (Fig. 1e).
- 149 We estimate only ~7% of mutations identified are likely attributable to false discovery
- 150 during variant calling, based upon background mutation rate in 75 BSMN neurotypical brain
- samples, and published experience from the BSMN^{12,18}, processed with the same workflow (see
- 152 Methods). Thus, 93% of our candidate MCD mutations would not have been identified in a size-
- 153 matched neurotypical control cohort.
- 154 Most patients (80.52%, 62 cases) showed a single somatic mutation, but some showed two
- somatic mutations (14.29%, 11 cases), and some showed more than two mutations (5.19%, 4
- 156 cases). Interestingly, HME-4144 showed 11 different somatic mutations, all of which were
- validated with TASeq. Although there are several possible explanations for HME-4144, we
- expect this reflects clonal expansion from a driver mutation, with detection of multiple passenger
 mutations, as reported in brain tumors¹⁹.
- 160 Single-base mutational signatures (SBS) were developed to describe potential mutational $\frac{20}{100}$ We for $\frac{1}{100}$ Single-base mutational signatures (SBS) were developed to describe potential mutational signatures (S
- 161 mechanisms in human disease²⁰. We found 60.2% of mutations were C>T, likely arising from 162 DNA epigenetic marks²¹ (Extended Data Fig. 2). Enrichment of SBS1 and SBS5, clock-like
- DNA epigenetic marks²¹ (Extended Data Fig. 2). Enrichment of SBS1 and SBS5, clock-like
 mutational signatures suggest endogenous mutations arising during corticogenesis DNA
- 165 Inutational signatures suggest endogenous inutations arising during correctigenesis DIVA
- 164 replication.
- 165

166 Functional dissection of the MCD genes

- 167 Interestingly, most validated genes were non-recurrently mutated (88.4%, 61 of 69) in our
- 168 cohort, suggesting substantial genetic heterogeneity in MCD. This nevertheless provided an
- 169 opportunity to study converging functional gene networks. Thus, we performed Markov
- 170 clustering with a STRING network generated from the putative MCD genes²², as well as recently
- 171 reported novel MCD candidates (*NAV2, EEF2, CASK, NF1, KRAS, PTPN11*)^{23,24} (Fig. 2a). We
- identified four clusters, with cluster 1 ("mTOR pathway") showing the highest term enrichment
- to the mTOR/MAP kinase signaling, supporting prior results for Type II MCDs. Cluster 1 also
- 174 highlighted newly identified genes *FGFR2*, *KLHL22*, *RRAGA*, *PPP2R5D*, *PIK3R3*, *EEF2*,
- 175 *EIF4G1*, and *MAPK9*. Cluster 2 identified "Calcium Dynamics" and included genes *ATP2A1*,
- 176 *RYR2, RYR3, PSEN2, TTN, UTRN.* Cluster 3 labeled "Synaptic Functions" and included genes
- 177 CASK, GRIN2C, and PPFIA4. Cluster 4 labeled "Gene Expression" and included intellectual
- disability genes, mostly involved in nuclear function, including NUP214, PRR14, PCNT, NIPBL,
- 179 SRCAP, ASH1L, TRIP12, and MED13 (Fig. 2b).
- Notably, *ATP2A1*, *PPFIA4*, and *NIPBL* were recurrently mutated, either within our
 cohort or with a recent report²⁴ (Extended Data Fig. 3a-b), occurring withing the latter 3 clusters.

182 While these clusters were not previously reported in MCDs, they were previously implicated in

183 epilepsy, neurodevelopmental and neurodegenerative disease^{25,26}, suggesting functional overlap

- 184 with MCDs. We further performed ClueGO analysis and found enrichment in mTOR signaling,
- 185 focal adhesion assembly, cardiac muscle cell contraction, and artery morphogenesis (Extended
- 186 Data Fig. 4). ClueGO also displayed isolated gene ontology (GO) term clusters such as 'calcium
- 187 ion import' and 'protein localization to synapse'.
- 188

189 Functional validation of selected module genes in embryonic mouse brain

190 To investigate the roles of novel MCD genes and modules, we selected two potential mTOR

- 191 pathway mutations (*RRAGA* p.H226R, *KLHL22* p.R38Q), and non-mTOR gene mutation
- 192 (*GRIN2C* p.T529M), discovered in FCD-7967, 3560, and 5157, respectively. *RRAGA* encodes
- Ras-related GTP binding A (RAGA), a GTPase sensing amino acid and activating mTOR
 signaling, with two functional domains: GTPase domain and C-terminal 'roadblock' domain
- $(CRD)^{27}$. The mosaic p.H226R mutation occurs within the CRD, which binds to the RAGB
- protein and is conserved throughout vertebrate evolution (Extended Data Fig. 3c) and thus could
- 197 change binding affinity. *KLHL22* encodes a CUL3 adaptor, determining E3 ubiquitin ligase
- 198 specificity. The CUL3-KLHL22 complex mediates degradation of DEPDC5, required for
- 199 MTORC1 activation²⁸. The KLHL22 p.R38Q variant in FCD-3560 is near the BTB (Broad-
- 200 Complex, Tramtrack and Bric a brac) domain that interacts with CUL3 (Extended Data Fig. 3d),
- suggesting the variant could enhance MTORC1 activity. *GRIN2C* encodes a subunit of the
 NMDA receptor regulating synaptic plasticity, memory, and cognition^{29,30}, dysfunction of which
- is implicated in many neurocognitive diseases including epilepsy, neurodevelopment, and
- tumors^{31,32}. *GRIN2C* p.T529M mutation is located in the S1 glutamate ligand-binding domain
 (S1 LDD) (Example 1 DD) (Example 2 D) (GDI)(24 E521) (Example 1 D) (GDI)(24 E521) (Example 2 D) (Example 2
- (S1 LBD) (Extended Data Fig. 3e). *GRIN2A* p.T531M mutation, an analog mutation of *GRIN2C* p.T529M in our cohort, was previously reported in epilepsy-aphasia spectrum disorders, where it
 increased NMDA receptors 'open-state' probability³². This suggests that the p.T529M mutation
 activates the channel, likely in an mTOR independent fashion. Thus, all mutations assessed here
- are likely gain-of-function and exert functional impact on cells in which they are expressed.
 To test this hypothesis, we introduced mutant or wildtype (WT) genes co-expressing
- To test this hypothesis, we introduced mutant or wildtype (WT) genes co-expressing enhanced green fluorescent protein (EGFP) into the dorsal subventricular zone via
- electroporation at mouse embryonic day 14 (E14), then harvested tissue at either E18 to assess
- 213 migration, or at postnatal day 21 (P21) to assess cell size and phospho-S6 as a reporter of mTOR
- activity³³ (Fig. 3a). In E18 cortices, we found EGFP-positive cells expressing mutant but not WT
- 215 forms of *RRAGA* and *KLHL22* showed significant migration defects of varying severity, whereas
- 216 mutant *GRIN2C* showed no defect (Fig. 3b). These migration defects in *RRAGA* and *KLHL22*
- 217 mutant cells replicate major findings of MCD disrupted cortical architecture.
- We next assessed cellular phenotype at P21 with samples available in both mice and the corresponding patients, and found enlarged cell body area in both mutant form of *KLHL22* and *GRIN2C* compared to according wildtype. In contrast, the elevated levels of pS6 staining, described previously in association with mTOR pathway mutations⁶, was found only in mutant *KLHL22*, but not in mutant *GRIN2C* mice (Fig. 3c).
- To assess correlation with human samples, we assessed archived neuropathological tissue sections for histology and pS6 activity. Similar to our mouse models, we found patient FCD-3560 carrying *KLHL22* p.R38Q showed enlarged neurons that co-stained for excess pS6 staining,
- whereas FCD-5157 carrying *GRIN2C* p.T529M showed only a slight increase in cell body size

and no evidence of excessive pS6 staining (Fig. 3d). While this analysis does not take into 227

account the genotype of individual cells, it suggests KLHL22 but not GRIN2C mutations impact 228

229 mTOR signaling.

230

231 Genotype-phenotype correlations in MCD patients

To assess the phenotypic contributions of the MCD genes we found, we focused on 76 of our 232 'genetically solved' MCD cases, comparing detailed neuropathology, brain imaging, and clinical 233 course. We performed Pearson correlation followed by hierarchical clustering based upon ILAE 234 neuropathological diagnosis, compared with GO term-based curated genesets and whether the 235 genetic variant was present in COSMIC DB (Methods, Supplementary Table 3,4, Fig. 4). We 236 237 found that FCD Type IIA and Type IIB, and HME were more tightly clustered than FCD Type I 238 or III (Fig. 4a), likely reflecting shared neuropathological features that include large dysplastic neurons. As expected, FCT Type IIA, Type IIB, and HME were positively associated with the 239 mTOR pathway GO term and COSMIC DB entry, FCD Type III, however, was associated with 240 the MAPK pathway, consistent with recent publications implicating BRAF, FGFR2, NOD2, and 241 MAPK9 in their etiology³⁴⁻³⁶. FCD Type I showed few strong positive correlations except for 242

243 Glycosylation, consistent with recent associations with *SLC35A2* and *CANT1*^{37,38}.

244 We next investigated correlations between clinical phenotypes extracted from detailed 245 medical records including seizure type, neuropsychological examination, and positron emission tomography (PET) metabolism, often used to help localize seizure focus^{39,40}. Seizure frequency, 246 early age of onset, Engel score, and history of infantile spasms drove clinical clustering, likely 247 248 reflecting shared clinical features in the most challenging patients. Focusing on the correlations, PET hypometabolism correlated positively with COSMIC DB entry, and negatively with MAPK 249 250 and Ubiquitination (Fig. 4b), suggesting divergent metabolic mechanisms. Abnormal

- 251 neurological examination correlated positively with COSMIC DB entry and negatively with
- 252 Type I histology, which may reflect the effects of mutations on baseline neurological function.
- 253

254 MCD genes enriched in the excitatory neuronal lineage

To infer the cell type in which MCD genes function, we accessed a published single-cell 255 transcriptome dataset from the 2nd-trimester human telencephalon, at a time when these

- 256 mutations probably arose⁴¹ (Fig. 5a). We generated an eigengene, by mapping the average
- 257
- 258 expression of our MCD genes against the UMAP plot (Fig. 5b). This showed a strong positive
- 259 correlation with dividing radial glial cells, a moderate correlation in dividing intermediate progenitor cells (IPCs) and mature excitatory neuron cells. We found a negative correlation with 260
- inhibitory neuronal lineages including medial and central ganglionic eminences (MGE, CGE) 261
- 262 and mature interneuron clusters (Fig. 5c). We next performed deconvolution into four major
- module eigengene (MEs), which revealed cell types classified as mature excitatory neurons 263
- 264 (turquoise and blue), microglia (brown), and unassigned (grey) (Fig. 5d). Ouantification
- supported enrichment in dividing radial glia, excitatory neurons, and microglia, the latter likely 265
- driven by MCD candidate genes IRF8 and VSIG4 (Fig. 5e). Taken together, the expression of 266
- MCD genes is more enriched in dorsal cortex neurogenic pools and implicated in the maturation 267
- of excitatory rather than inhibitory neurogenic pools, as well as microglia. 268
- 269

270 MCD gene expression is enriched in dysplastic cells

271 We next performed differentially expressed gene (DEG) analysis in the MCD brain. We

reasoned that single-nucleus transcriptomes would be more revealing than bulk transcriptomes,

but the average VAF of ~6% in our MCD cohort meant that the vast majority of sequenced cells

would be genetically wild-type. We thus decided to focus snRNAseq on resected cortex from

275 patients with shared pathological MCD hallmarks but higher VAFs. We selected four resected

brain samples, two from patients with HME (HME-4688 PIK3CA p.E545K, 25.1% VAF and

HME-6593 *PIK3CA* p.H1047R, 13.1% VAF), and two from patients with TSC meet full
 diagnostic criteria. We also included brains from four neurotypical cases as a comparison and

sequenced a total of 22,067 cells (see Methods).

280 While the TSC brain single nucleus transcriptomes showed substantial overlapping pools 281 with controls, HME brains showed a distinct UMAP distribution, located at the edges of the plot 282 (Fig. 6a). We found that very few HME cells matched expression patterns for typical brain cells, 283 even after standard normalization and scaling (Fig. 6b, Extended Data Fig. 5a, see Methods). We 284 thus labeled these clusters according to their closest relatives based upon established marker 285 gene expression in the control brain, labeled as 'astrocyte-like (Ast-L)' or 'oligodendrocyte-like 286 (OD-L)'. Even with these categories, some clusters remained undefined (U) (Extended Data Fig. 5b,c). Interestingly, there was no single cell cluster that matched the VAF in the brain, 287 288 suggesting the mutant cells, as well as surrounding non-mutant cells, have dramatically disrupted 289 transcriptomes.

290 We noted that several of the HME clusters showed excessive expression of fibroblast 291 growth factor receptor (FGFR) gene families, specifically FGFR1 in cluster U1/2 in HME, FGFR2/3 in cluster Ast-L1/3 and OD-L, EGFR in Ast-L1/3 and U1/2, and PDGFRA in cluster 292 293 U1/2 (Extended Data Fig. 5b,c). To identify the cell types expressing these genes, we performed 294 RNA in situ hybridization in HME brain sections followed by hematoxylin-eosin staining. We 295 found co-localization of these same FGFR family, EGFR, and PDGFRA transcripts with 296 dysplastic cells (Extended Data Fig. 6). Previous experiments suggest that it is most often the 297 dysplastic cells within HME and MCD that carry disease mutations⁷, suggesting an effect of these mutations on growth factor receptor expressions that correlates with dysplasia. 298

299 Next, we investigated the expression patterns of MCD genes in this HME/TSC snRNAseq dataset. An eigengene representing expression patterns of MCD genes was enriched 300 301 in Ast-L1/3 and OD-L, which were labeled as dysplastic cells (Fig. 6c). Interestingly, the 302 individual MCD genes displayed converging expression patterns resulting in six different 303 eigengenes (Fig. 6d, gene members for each eigengene are described in Extended Data Fig. 7) 304 which show distinct enrichment patterns across cell types (Fig. 6e), implying that membership of 305 each eigengene may be associated with the pathophysiology of the corresponding dysplastic cell 306 type in HMEs. We performed a pseudo-bulk DEG analysis comparing HME with CTRL and 307 detected 590 up-regulated genes and 1096 down-regulated genes. Intriguingly, 20% (15/75) of 308 MCD mutated genes in our list overlapped with DEGs of HME. Permutation testing suggests that this overlap is unlikely to have arisen by chance (Fig. 6f, see Methods). Taken together, 309 310 many MCD genes are misregulated in MCD-specific cell types, suggesting that our MCD genes

311 may play important roles in the pathogenesis of dysplastic cells in MCDs.

312

313 Discussion

In this study, we use a multiomics approach to study the genetic landscape of MCD in the largest

315 reported cohort to date. We confirmed the important role of mTOR/MAP kinase and

316 glycosylation pathways, seen in about 60.5% of those with mutations. Moreover, our results also

317 linked novel biological processes including gene expression, synaptic function, calcium

- dynamics, which made up the other 39.5% of mutations. Nevertheless, only 76 of 317 patients
- 319 showed one or more putative somatic mutations as a likely cause of MCD. There could be
- 320 numerous causes for the relatively low solve rate in MCD, including the potential to miss very
- 321 low VAF mutations and the contribution of complex mutations like structural variants or short
- tandem repeats polymorphism. Finally, although patients with environmental causes, syndromic,
- 323 or inherited causes were excluded from our cohort, these factors could still contribute to MCD.

324 With our approach, we identified several recurrently-mutated genes not previously 325 implicated in MCD. Confirming the remaining candidate and identifying further MCD candidate 326 genes will require larger MCD cohorts. Including novel MCD candidate genes emerging from 327 300X WES into the 1000X Phase 3 AmpliSeg allowed both confirmation of mutations, a more 328 accurate estimate of VAF, and identification of additional patients with these genes mutated that 329 would have been perhaps missed with 300X WES. Functional validation by modeling mutations 330 in embryonic mouse brains suggests that most candidate genes we identified are likely to 331 contribute to disease. Perhaps it is not surprising that there are so many MCD genes, because 332 such mutations may avoid embryonic lethality due to their expression in just a small subset of 333 cells. Like with de novo germline mutations discovered in autism, we suggest that there could be 334 dozens if not hundreds of additional MCD genes, based in part upon the low number of recurrently mutated genes ⁴². 335

336 The four gene networks, mTOR/MAP kinase, calcium dynamics, synapse, and gene expression, are intriguing, as they should play important roles of these genes both during brain 337 338 development and homeostasis. All four pathways are critical both for corticogenesis during 339 neurogenesis and neuronal migration, as well as neuronal excitability. For instance, calcium dynamics is shown to regulate cytoskeletal activity and excitability^{43,44}. The genotypic 340 information also showed correlations with clinical features, for instance, PET brain 341 342 hypometabolism and abnormality in the neurological examination correlated with COSMIC DB variants, opening the possibility to predict genotype based on phenotype. 343

We also characterized the expression patterns of MCD genes in the developmentally 344 normal and MCD brains at single-cell resolution. The cell types most strongly expressing 345 candidate MCD genes include dorsal forebrain radial glial progenitors and their daughter 346 excitatory neurons, as well as brain microglia, fitting well with the likely site of origin of somatic 347 brain mutations⁴⁵. Surprisingly, the dramatic gene dysregulation seen in the HME brain skewed 348 349 the UMAP plots in ways that could not be accounted for simply by the VAF. The fact that the 350 MCD genes also showed the strongest enrichment with these same clusters suggests that the MCD genes are very likely to have pivotal roles in the HME condition. Prior studies on MCD 351 indicated that dysplastic cells express markers for both glia and neurons⁴⁶. Our findings, 352 however, suggest that MCD mutations drive critical roles predominantly in dividing radial glia, 353 with profound effects on lineage and cellular dysplasia. To conclude, the MCD genes in patient 354 355 brains found in our study demonstrated critical roles during cortical development, significantly correlate with patient phenotypes, and could open doors to novel treatments for MCDs. 356 357

358 **Online Methods**

359

360 **Overview of the FCD cohort**

361 This study is a multi-center international collaboration. We recruited a cohort of 317 individuals

from 'FCD Neurogenetics Consortium' (see the member list). These individuals were diagnosed

with FCD type I, II, III, HME, or TSC and underwent surgical resection to treat drug-resistant

- epilepsy between 2013-2021. Any case underwent surgical resection due to environmental
 factors ,for example stroke, acute trauma, were excluded. For each individual, resected brain
- factors for example stroke, acute trauma, were excluded. For each individual, resected brain tissue was collected, along with paired blood or saliva samples and parental samples, where
- available. Clinical history, pre- and post-operative brain imaging, histopathology, ILAE
- 368 classification according to surgical tissue pathology report, and Engel surgical outcome score (at
- least two years after surgery) were collected, when available.
- 370

371 Informed consent and study approval

- The study protocol was approved by the UC San Diego IRB (#140028). Informed consent was
- 373 obtained from all participants or their legal guardians at the time of enrollment.
- 374

375 **DNA extraction**

- Pulverized cortical samples (~0.3 g) were homogenized with a Pellet Pestle Motor (Kimble,
- 377 #749540-0000) or Handheld Homogenizer Motor (Fisherbrand, #150) depending on the size of
- the tissue, and resuspended with 450 µL RLT buffer (Qiagen, #40724) in a 1.5 ml
- 379 microcentrifuge tube (USA Scientific, #1615-5500). Homogenates were then vortexed for 1
- minute and incubated at 70°C for 30 minutes. 50 µl Bond-Breaker TCEP solution (Thermo
- 381 Scientific, #77720) and 120 mg stainless steel beads with 0.2 mm diameter (Next Advance,
- 382 #SSB02) were added, and cellular disruption was performed for 5 minutes on a DisruptorGenie
- 383 (Scientific industries). The supernatant was transferred to a DNA Mini Column from an AllPrep
- 384 DNA/RNA Mini Kit (Qiagen, #80204) and centrifuged at 8500 xg for 30 seconds. The column
- 385 was then washed with Buffer AW1 (kit-supplied), centrifuged at 8500 xg for 30 seconds and
- 386 washed again with Buffer AW2 (kit-supplied), and then centrifuged at full speed for 2 minutes.
- The DNA was eluted two times with 50 μ l of pre-heated (70°C) EB (kit-supplied) through
- centrifugation at 8,500 xg for 1 minute.
- 389

390 MPAS and WES sequencing for somatic mutation candidates

- 391 Massive parallel amplicon sequencing (MPAS) and whole-exome sequencing (WES) were used
- 392 at different phases to perform the genetic screening within available samples from the cohort.
- Customized AmpliSeq DNA panels for Illumina (Illumina, #20020495) were used for Massive
- Parallel Amplicon Sequencing¹⁷. 87 or 82 genes related to the mTOR pathway or curated based
- 395 on the results of Phase 1 and 2, respectively, were subjected to the AmpliSeq design system; a
- list of designed genes is provided in Supplementary Table 2a-b. Two pools were designed for tiling the centure region. Conomia DNA from extracted tissue was diluted to 5 ng/uL in law TE
- tiling the capture region. Genomic DNA from extracted tissue was diluted to 5 ng/uL in low TE provided in AmpliSeq Library PLUS (384 Reactions) kit (Illumina, #20019103). AmpliSeq was
- carried out following the manufacturer's protocol (document #1000000036408v07). For
- amplification, 14 cycles each with 8 minutes were used. After amplification and FUPA
- 401 treatment, libraries were barcoded with AmpliSeq CD Indexes (Illumina, #20031676) and pooled

with similar molecular numbers based on measurements made with a Qubit dsDNA High
Sensitivity kit (Thermo Fisher Scientific, #Q32854) and a plate reader (Eppendorf, PlateReader
AF2200). The pooled libraries were subjected to Illumina NovaSeq 6000 platform for PE150
sequencing. The AmpliSeq design in the 'Phase 1' is under the design ID IAA7610, and the
AmpliSeq design in 'Phase 3' is under the design ID IAA26010.

 $\begin{array}{ll} \mbox{407} & \mbox{Genomic DNA (\sim 1.0 μg$) was prepared for whole-exome sequencing, and libraries were captured using the Agilent SureSelect XT Human All Exon v.5 or Nextera DNA Exome kits. \\ \mbox{409} & \mbox{Then, 100, 125, or 150 bp paired-end reads (median insert size \sim 210 bp) were generated using the Illumina HiSeq X 2500 platform. The sequencing experiments were designed to yield three \\ \end{array}$

- 411 datasets of ~ 100X coverage on each sample, with a coverage goal of 300X from the brain and
- 412 100X from blood/saliva.
- 413

414 Somatic variant calling from MPAS and WES

Reads were aligned to GRCh37 using BWA (version 3.7.16a), sorted per each read group, and
merged into a single BAM file with sambamba (version 0.6.7). The merged BAM files were
marked for duplicate reads using PICARD (v2.12.1), duplicated reads were not removed for
MPAS because of the nature of the method. Then, we performed indel realignment and base
quality recalibration using GATK (v3.7–0), resulting in the final uniformed processed BAM
files.

- Both tissue-specific and tissue-shared mosaic variants were called from the MPAS and 421 422 WES sequencing data. MPAS and WES variants were called according to the availability of the 423 control tissue. Brain- and blood/saliva-specific variants were called using MuTect2 (GATK3.8) paired mode and Strelka2 somatic mode⁴⁷; the BAM files from the brain sample (combined and 424 425 non-combined from independent sequencing libraries) and blood/saliva samples were treated as "tumor-normal" and "normal-tumor" pairs separately and cross-compared between each other. 426 Variants called by both callers were listed. Mosaic variants shared between the brain and 427 fibroblast samples were called using the single mode of MosaicHunter¹¹ by either combining all 428 brain replicates or calling each separate sample. Variants that passed all the MosaicHunter filters 429 also were listed. Somatic variants from WES data were further called by GATK (v3.7–0) 430 haplotypecaller with ploidy parameter set to 50, followed by a series of heuristic filters described 431 as the best-practice by the Brain somatic mosaicism network¹², tissue-shared variants were called 432 by the combination of MuTect2⁴⁸ (GATK 3.8) single-mode and DeepMosaic¹⁰. 433 434 A union of different pipelines was selected to get maximum sensitivity. Mosaic candidates from the combined lists were further filtered using the following criteria: (i) the 435 436 variant had more than 3 reads for the alternative allele; (ii) the variant was not present in UCSC repeat masker or segmental duplications; (iii) the variant was at least 2 bp away from a 437 homopolymeric tract; and (iv) the variant exhibited a gnomAD allele frequency lower than 438 439 0.001. Variants that exist in the 1000 genome project (phase 3) also were excluded from the analysis. Variants from both exome data sources were tested and a combination of tissue-specific 440 441 mosaic variants and tissue-shared mosaic variants were collected and the credible interval of VAFs was calculated using a Bayesian-based method described previously⁴⁹. To filter for 442 candidate disease-causing variants for FCD, we further filtered out synonymous variants in 443 coding regions, variants with CADD Phred score < 25, and candidates that fell out of coding 444
- 445 regions and were not predicted to affect splicing by ANNOVAR.

446 False discovery estimation

- 447 To calculate false discovery of random variants detected in normal samples, we incorporated 75
- 448 normal control samples (71 brains and 4 other organs) previously sequenced with 250-300X
- 449 WGS, which should provide similar sensitivity as our exomes, the deep WGS were generated by
- 450 efforts from the NIMH Brain Somatic Mosaicism Consortium¹², from controls¹⁷, and from our
- 451 recent mutation detection pipeline¹⁸. Variants were filtered based on the identical criteria as
- 452 described in the above data analysis part, with >0.01 VAF, all on exonic regions defined by
- 453 NCBI, and CADD score >25. While 13 variants remain positive from this pipeline from the 75
- 454 samples (0.17 per control), 306 candidate variants were determined in our 134 MCD exomes
- 455 (2.28 per MCD case), which lead to an estimated 7.59% per sample false discovery rate
- 456 (Supplementary Table 5).

457 Orthogonal validation and quantification of mosaic mutations with targeted amplicon 458 sequencing

- 459 Targeted amplicon sequencing (TASeq) with Illumina TruSeq was performed with a coverage
- 460 goal of >1000X for 554 candidate variants detected by computational pipelines described above
- for both MPAS and WES, to experimentally validate the mosaic candidates before functional
- 462 assessment. PCR products for sequencing were designed with a target length of 160-190 bp with
- 463 primers being at least 60 bp away from the base of interest. Primers were designed using the
- 464 command-line tool of Primer $3^{50,51}$ with a Python (v3.7.3) wrapper^{13,14}. PCR was performed
- according to standard procedures using GoTaq Colorless Master Mix (Promega, M7832) on
- sperm, blood, and an unrelated control. Amplicons were enzymatically cleaned with ExoI (NEB,
- 467 M0293S) and SAP (NEB, M0371S) treatment. Following normalization with the Qubit HS Kit
- 468 (ThermFisher Scientific, Q33231), amplification products were processed according to the
- 469 manufacturer's protocol with AMPure XP beads (Beckman Coulter, A63882) at a ratio of 1.2x.
- 470 Library preparation was performed according to the manufacturer's protocol using a Kapa Hyper
- 471 Prep Kit (Kapa Biosystems, KK8501) and barcoded independently with unique dual indexes
- 472 (IDT for Illumina, 20022370). The libraries were sequenced on Illumina HiSeq 4000 or NovaSeq
- 473 6000 platform with 100 bp paired-end reads.
- 474

475 Mutational signature analysis

- 476 Mutational signature analysis was performed using a web-based somatic mutation analysis
- 477 toolkit (Mutalisk)⁵². PCAWG SigProfiler full screening model was used.
- 478

479 STRING analysis

- 480 STRING analysis was performed by STRING $v11^{22}$. A total of 75 MCD genes were loaded as
- 481 input and MCL clustering was performed. The terms in Gene Ontology (GO), KEGG pathways,
- 482 Top 10 terms GO or KEGG pathways were shown in Fig. 2b. If there are less than 10 terms for
- those terms (such as clusters 3 and 4 in Fig. 2), we included all the terms in GO or KEGG
- 484 pathways, Local network cluster (STRING), Reactome pathways, and Disease-gene associations
- (DISEASES) to show the enriched terms. Visualization was performed by Cytoscape v3.9.
- 486
- 487 ClueGO

488 Visualization of the functionally grouped biological terms was performed by ClueGO v2.5⁵³, a

489 Cytoscape plug-in. A total of 75 MCD genes from Fig. 2 were loaded and GO terms in the

- 'Biological Process' category were used for visualization. Terms with a p < 0.01, a minimum
- 491 count of 3, and an enrichment factor > 1.5, are grouped into clusters based on membership
- 492 similarities.
- 493

494 Animals

- 495 Pregnant Crl: CD1(ICR) mice for mouse modeling were purchased from Charles River
- 496 Laboratory. All mice used were maintained under standard group housing laboratory conditions
- 497 with 12 hours light/dark cycle and free access to food and water. The age and number of mice
- used for each experiment are detailed in the figure legends. The sex of the embryos used was not
- tested. All work with mice was performed in accordance with UCSD IACUC protocol \$15113.
- 500

501 **DNA constructs**

- 502 *RRAGA*, *KLHL22*, and *RHOA* ORF regions were amplified from the hORFeome library and
- inserted into the pCIG2 (pCAG-IRES-GFP) vector. *GRIN2C* ORF region was purchased from
 DNASU Plasmid Repository in Arizona State University Biodesign Institute. All sequences of
- 505 clones were confirmed by sanger sequencing.
- 506

507 In utero electroporation

- In utero electroporation was performed as described previously⁵⁴ with modifications as follows.
- 509 Endotoxin-free plasmids (0.5–1 µg) plus 0.1% Fast Green (Sigma, catalog no. 7252) was injected
- 510 into one lateral ventricle of E14.5 embryos. Electroporation was performed by placing the anode
- 511 on the side of the DNA injection and the cathode on the other side of the head to target cortical
- 512 progenitors. Four pulses of 45 V for 50 ms with 455-ms intervals were used.
- 513

514 Mouse brain section preparation

- An E18 mouse brain is fixed in 4% paraformaldehyde (PFA) for 2 hrs. For the P21 mouse brain,
- a mouse was anesthetized by isoflurane and perfused by cold 1X PBS for 8 min and following
- 517 4% cold PFA for 8 min. The brains were dehydrated in 30% sucrose in 1x PBS for 48 hrs and
- 518 embedded in Tissue-Tek optimal cutting temperature compound and frozen on dry ice. A frozen
- 519 block was sectioned with 20 um thickness in a cryostat (CryoStar NX70, Thermo Fisher
- 520 Scientific) and placed on sliding glass. The attached sections were dried on a 50 °C heating block
- 521 for 3 hrs.
- 522

523 Immunofluorescence staining and imaging

- A section was rehydrated and washed by 1X PBS for 10 min 3 times, permeabilized in PBST
- 525 (0.3% Triton X-100 in 1X PBS) for 10 min, and blocked by blocking solution (5% normal BSA
- 526 in 1X PBS) for 2 hrs in room temperature. Sections were stained with diluted primary antibodies
- 527 in the blocking solution overnight at 4 °C. The next day, the sections were washed with PBST for
- 528 5 min three times and stained with secondary antibodies in blocking solution for 2 hrs in RT.
- 529 Blocking solution was dropped off from the slides and nuclei staining with DAPI solution
- 530 (0.1ug/ml of DAPI in PBST) was performed for 15 min. The slides were mounted with DAKO

fluorescent mount solution (catalog no. S3023). Zeiss 880 Airyscan Confocal is used for imaging
 according to the manufacturer's instructions.

533

534 Antibodies

phospho-S6 (1:800 dilution, catalog no. 5364S ;Cell Signaling, AB_10694233), NeuN (1:100,

536 MAB377X; Sigma-Aldrich, AB_2149209), GFP (1:500, catalog no. GFP-1020, Aves Labs,

537 AB_10000240), Alexa Fluor Goat 488 chicken IgY (H+L) (1:1,000 dilution, catalog no. A-

538 11039, AB_2534096), Alexa Fluor 594 donkey anti-rabbit lgG (H+L) (1:1,000, catalog no.

- 539 R37119, AB_2556547).
- 540

541 Genotype-phenotype association

542 The functional modules to be tested were selected based on the enriched GO terms (Fig. 2 and

543 Extended Data Fig. 4). A given candidate MCD gene was assigned as a member to one or

- 544 multiple modules based on GO terms related to the given gene (results summarized in
- 545 Supplementary Table 3c). Subsequently, a given patient became a member of one (or multiple)
- 546 functional module(s) if the genes detected in that patient was assigned to that (those) functional
- 547 module(s). All available clinical information on the patient was collected and harmonized using
- 548 ILAE terms (summarized in Supplementary Table 4). Pearson correlation coefficients were
- calculated by cor.test() function in R. The value of correlation coefficients were displayed as
- colors in heatmap of Fig. 4. If two groups with binary values were used for calculation, Phicoefficient was used.
- 552

553 Single-nucleus RNA sequencing

A fresh-frozen brain tissue (~50 mg) was placed into a glass dounce homogenizer containing 1 554 555 ml cold lysis buffer (0.05 % (v/v) NP-40, 10 mM Tris (pH 7.4), 3 mM MgCl₂, 10 mM NaCl) and dounce 10 times with a loose pestle and following 10 times with a tight pestle. The homogenate 556 557 was incubated for 10 min in RT. 9 ml of wash buffer (1% BSA in 1X PBS) was added to the 558 homogenate and filtered by a 30 um cell strainer. The strained homogenate was spun down in 559 500 g to remove the supernatant. The pellet was resuspended by 5 ml of wash buffer. Straining, 560 spinning down steps was performed once more, and the pellet was resuspended into 500 ul of 561 wash buffer. 10 ul of nuclei resuspension was mixed with counting solution (0.02 % Tween 20, 562 0.1ug/ml DAPI, 1% BSA in 1X PBS) and nuclei density was measured by manual nuclei 563 counting using DAPI signal. The resuspension was diluted by wash buffer to make the desired

- 564 concentration (800~1000 nuclei/ul). 1~4 samples were pooled together targeting 10000 nuclei
- 565 per reaction. Gel beads emulsion (GEM) generation, cDNA, and sequencing library
- 566 constructions were performed in accordance with instructions in Chromium Single Cell 3'
- 567 Reagent Kits User Guide (v3.1). A library pool was sequenced with 800 million read pairs using
- 568 NovaSeq 6000.
- 569

570 Single-nucleus RNAseq bioinformatics pipeline

- 571 Fastq files from single-nucleus libraries were processed through Cell Ranger (v6.0.2) analysis
- 572 pipeline with –include-introns option and hg19 reference genome. Pooled library was
- 573 demultiplexed and singlets were taken by demuxlet. Seurat (v4) package was used to handle

- 574 single nuclei data objects. Protein coding genes were used for further downstream analysis.
- 575 Nuclei passed a control filter (number of genes > 500, number of reads >1000, percentage of
- 576 mitochondrial gene < 10%) was used for downstream analysis. Data were normalized and scaled
- 577 with the most variable 5000 features using the 'NormalizeData' and 'ScaleData' functions.
- 578 Dimensionality reduction by PCA and UMAP embedding was performed using runPCA and
- 579 runUMAP function. Clustering was performed by FindNeighbors and FindClusters function. Cell
- type identification was performed using known cell type markers expressed in the brain
- 581 including excitatory/inhibitory neuron, astrocyte, oligodendrocyte, microglia, and endothelial
- cell markers as well as using positive markers found by FindAllMarkers function with 3000 most
- 583 variable features in scaled data.
- 584

585 Weighted gene co-expression network analysis

- 586 'r-wgcna' package (v1.69) was used for WGCNA according to instructions (PMID: 19114008).
- 587 Briefly, a similarity matrix was generated based on Pearson's correlation coefficient value
- among the top 3000 variable features in single-nucleus transcriptome data, which was used to
- calculate the subsequently signed type of network adjacency matrix. Next, the topological
- 590 overlap matrix (TOM) and the corresponding dissimilarity (1-TOM) value were generated from
- the adjacency matrix. Finally gene modules were generated by 'cutreeDynamic' function with
- ⁵⁹² 'tree' method, minAbsSplitHeight = 0.9 and minClusterSize = 30 option. Similar gene modules
- were merged by 'mergeCloseModules' function with cutHeight = 0.25. String analysis was
- 594 performed using each gene module for the identification of the given module's functional 595 characteristics.
- 596

597 **RNAscope**

- 598 We used published methods and purchased target probes for genes of interest containing an 18-
- 599 25 base region complementary to the target, as spacer sequencing, and a 14 base Z-tail
- sequence⁵⁵, including RNA pol III positive control and random sequence negative control,
- 601 following the manufacturer recommendations (Advanced Cell Diagnostics, Hayward, CA).
- Images were acquired on a Leica STED Sp8 with Falcon microscope.
- 603

604 Permutation analysis for the enrichment of MCD genes

- To test the enrichment of differentially expressed MCD genes in RNA sequencing against a
- random distribution, we designed a permutation analysis. All human genes used in the single-cell
- 607 RNA-seq analysis (n=19909) were randomly shuffled 10,000 times and the same number of
- genes as described in the differential expression analysis (n=1686) was selected for each shuffle.
- The number of overlaps between each shuffle and the MCD candidates was compared and the
- number of overlaps was used as the outcome and a null distribution was generated from the
- 611 10,000 shuffles. All 75 positively validated MCD genes are confirmed to be existing in the initial
- $figure{1}$ gene list. After 10,000 permutations, the permutation p-value was calculated with numbers \geq
- big observed overlap (p=0.0017 for the data shown in the main text).
- 614

615 Statistical analyses

- 616 Statistical analyses were performed by R or Prism 8 (GraphPad Software). Two-way ANOVA
- and Sidak multiple comparisons were performed in Fig 3b with p-values of interaction between
- 618 genotype and bin factor. ****p < 0.0001, ***p < 0.001, **p < 0.001, *p < 0.05.
- 619

620 Code and data availability

- 621 Code to generate the figures and analyze the data are publically available on GitHub
- 622 (https://github.com/shishenyxx/MCD_mosaic). WES and AmpliSeq data are deployed on NIMH
- Data Archive under study number 1484 "Comprehensive multiomic profiling of somatic
- 624 mutations in malformations of cortical development" and SRA under accession number
- 625 PRJNA821916: "Comprehensive multiomic profiling of somatic mutations in malformations of
- 626 cortical development". The snRNAseq R object was deposited in Single Cell Portal
- 627 (https://singlecell.broadinstitute.org/single_cell/study/SCP1815/comprehensive-multiomic-
- 628 profiling-of-somatic-mutations-in-malformations-of-cortical-development#study-download).
- 629

630 Acknowledgments

- AmpliSeq, TASeq, and snRNAseq were supported by NIH P30CA023100 and S10OD026929 at
- the UCSD IGM Genomics Center. Rady Children's Institute for Genomic Medicine, Broad
- Institute (U54HG003067, UM1HG008900), the Yale Center for Mendelian Disorders
- 634 (U54HG006504), and the New York Genome Center provided whole-exome sequencing. UCSD
- 635 Microscopy core (NINDS P30NS047101) provided imaging support. CC was supported by a
- 636 2021 Brain & Behavior Research Foundation Young Investigator Grant. This study was
- 637 supported by the NIH (NIMH U01MH108898 and R01MH124890 to JGG and GWM, and NIA
- 638 R21AG070462, NINDS R01NS083823 to JGG). We thank St éphanie Baulac and Sara
- 639 Baldassari for sharing unpublished exome data.
- 640

641 **Author contributions**

- 642 C.C., X.Y., and J.G.G. designed the study. C.C., S.M., and S.K. conducted functional validation.
- 643 C.B., V.S., A.N., E.R., C.C., and G.H. coordinated the clinical database. X.Y., C.C., M.W.B.,
- 644 L.L.B., R.D.G., J.G., M.X., A.P.L.M., and K.N.J. organized, handled, and sequenced human
- samples. X.Y., C.C., T.B., X.X., and B.C. performed bioinformatics and data analysis. C.C. and
- 646 K.I.V. performed the RNAscope experiment. C.D., H.W.P., C.A.B.G., S.H.K., H.K., A.S.,
- 647 C.A.H., C.G., C.A.G., S.S., M.N., D.D.G., K.I., Y.T., R.C., J.T., V.C., R.G., O.D., W.A.S.,
- 648 H.R.M., and G.W.M. provided resected brain tissues and clinical data from FCD patients. C.C.,
- 649 X.Y., and J.G.G. wrote the manuscript. All authors read and commented on the manuscript
- 650 before submission.
- 651

652 Competing Interests Statement

- The authors declare no competing interests.
- 654
- 655




Figure 1. Comprehensive genetic profiling and validation of somatic variants in 327 MCD 657 patients. (a) Representative MRI image of FCD-3588 (FCD type I), FCD-4514 (FCD type II), 658 659 HME-1573, and a pie chart for the composition of our MCD cohort. Yellow arrow and dash: affected brain regions. (b) Workflow for comprehensive genetic profiling of MCD, using a three-660 phase approach from patient DNA. Each phase was followed by quantification/validation of each 661 662 variant with target amplicon sequencing (TASeq). Phase 1] $1000 \times \text{pilot}$ screening of DNA with an 87-gene mTOR-related panel. Phase 2] $300 \times$ whole-exome sequencing (WES) with and best-663 practice somatic variant discovery for novel candidate discovery. Phase 3] Cohort-level 664 validation with an updated, high-confidence TASeq gene set based on knowledge from Phase 1 665 666 and 2. A subset of the somatic mutations was further functionally validated by mouse modeling. Candidate genes were annotated and correlated with external datasets such as STRING DB, 667 clinical phenotype dataset, and newly generated single-nucleus RNAseq dataset from MCD 668 brain. (c) Somatic variant calls were detected from all three phases of genetic discovery, yielding 669 670 108 validated somatic calls. (d) Correlation between square-root transformed (sqrt) AmpliSeq/WES variant allele fraction (VAF) and TASeq VAF. Solid line: best-fit line linear 671 672 regression. Dotted lines: 95 % confidence band of the best-fit line. (e) Oncoplot with all 69 validated somatic SNVs from this study. Top: most patients had one gene mutated, a few patients 673 had more than one gene mutated, and patient HME-4144 had 11 different validated gene 674 675 mutations. Color: type of variant. * and #: recurrent genes in our cohort, and non-recurrent in our cohort but recurrent in other studies, respectively. 676







Figure 2. Four major gene networks were discovered from the comprehensive MCD gene

- 679 **profiling.** (a) STRING DB pathway analysis of the 69 MCD discovered genes and six novel
- genes from recent publications identifies MTOR/MAP kinase pathway (pink, Cluster 1),
- 681 Calcium dynamics (green, Cluster 2), Synapse (purple, Cluster 3), Gene expression (blue,
- 682 Cluster 4). Edge thickness: confidence score calculated by STRING. Size and color of a node:
- square root transformed (sqrt) number of patients carrying a given mutation and average sqrt
- 684 VAF across all patients, respectively. Non-clustered orphan genes are listed on the right. Red
- border: variant reported in the COSMIC database. (b) Gene Ontology (GO) analysis results
- confirmed the functions of compositions in each network. Top GO terms or KEGG pathways.
- 687 Strength calculated by STRING.
- 688








710 Figure 4. Clinical phenotypic outcomes correlate with genotype-based classifications in

- 711 **MCD.** (a) Correlation heatmap for classification based on genetic information (y-axis) vs.
- 712 International League Against Epilepsy (ILAE) classification based on histology (x-axis) using
- 713 Pearson correlation. Shade: value of Phi coefficient. Note Type IIA and HME are enriched with
- 714 mTOR and Ubiquitination genes, while Type I is enriched in Glycosylation and depleted in
- 715 MTOR and COSMIC genes. HME: hemimegalencephaly. (b) Correlation between classification
- based on genetic information and various clinical phenotypes. Shade: value of Phi (binary data)
- or Pearson (continuous) correlation coefficient. For example, positron emission tomography
- 718 (PET) hypometabolism is enriched in COSMIC genes and depleted in MAPK pathway, whereas
- abnormal neurological examination is enriched in COSMIC genes. The whole dataset is in
- 720 Supplementary table 4.




722

Figure 5. Single-nucleus transcriptomes reveal MCD gene enrichment in radial glia and 723

excitatory neurons in the developing human cortex. (a) Uniform Manifold Approximation and 724

Projection (UMAP) for single-nucleus transcriptome in 2nd trimester fetal human telencephalon 725

- from a public dataset⁴¹. (b) UMAP enrichment patterns of an eigengene using MCD genes. Note 726 enrichment for excitatory neurons and radial glia (dark brown). vRG: vertical radial glia, tRG: 727
- truncated radial glia, RG-div: dividing radial glia, oRG: outer radial glia, EN: excitatory neuron, 728
- 729 nEN: newborn excitatory neuron, IPC: intermediate progenitor cell, STR: striatum, IN:
- 730 interneuron, CTX: cortex, MGE: medial ganglionic eminence, CGE: central ganglionic
- 731 eminence. (c) Quantification of enrichment of (b) based on cell types, showing enrichment for
- RG-div. (d) Four eigengenes decomposed from (b). (e) Quantification of enrichment of (d) based 732
- on cell types showing enrichment in dividing radial glia, microglia and inhibitory cortical 733
- neurons from the medial ganglionic eminence (MGE). 734




739	Figure 6. Single-nucleus transcriptomes showed MCD gene expression enriched in MCD-
740	specific cell types. (a) UMAP for single-nucleus transcriptome of 22067 nuclei from the cortical
741	lesions of control (CTRL), hemimegalencephaly (HME), and tuberous sclerosis complex (TSC)
742	brain. (b) Cell type classification. Ast: astrocyte, ExN: excitatory neuron, InN: inhibitory neuron,
743	MG: microglia, OD: oligodendrocyte, U: unidentified. (c) The expression pattern of an
744	eigengene made with all MCD genes and the quantification of enrichment based on cell types.
745	(d) Six eigengenes decomposed from (c). (e) Quantification of the cell-type-specific enrichment
746	in (d). (f) A volcano plot from DEG list of HME versus CTRL pseudo-bulk data. The genes
747	having adjusted $p < 10^{-305}$ were pointed by arrow. (g) The MCD genes overlapping with DEGs of
748	HME in contrast to controls. Permutation test (10,000 times) shows a very rare chance (p <
749	0.0017) to show this overlap in a random sampling of 1686 genes from 19909 protein-coding
750	genes used in these DEGs. Red or blue coloring of gene names indicates upregulated or
751	downregulated DEGs in HMEs compared to CTRLs, respectively.
752	

753 Supplementary Table Descriptions

754 Supplementary Table 1. The cohort list and corresponding sequencing methods. The 327 cases are listed in each row and corresponding sequencing methods used for a given sample was 755 756 described. 757 758 Supplementary Table 2. AmpliSeq primer pool designs (a) Ampliseq primer pool design used 759 in phase 1. (b) Ampliseq primer pool design used in phase 3. 760 Supplementary Table 3. The summary of SNV calls across the three phases of genetic 761 762 discovery. (a) 1811 raw calls derived from the combination of variant callers described in 763 Extended Data Fig. 1. (b) 554 input SNV calls participated in TASeq quantification. (c) 764 Validated brain somatic SNV calls from (b). (d) Annotation table of the genes listed in (c) based 765 on GO terms. 766 767 Supplementary Table 4. The summary of phenotype and genotype information for the 768 'genetically solved' cases. 769 Supplementary Table 5. The summary table used for false discovery estimation. 770 771


772



773 774

775 Extended Data Fig. 1 Bioinformatic pipeline to detect somatic SNVs in the MCD cohort. (a)

- The pipeline for paired samples. Notably, the dashed square indicates that the sharing variants
- between MuTect2 paired mode and Strelka2 were used for the downstream analysis. BSMN
- common pipeline and DeepMosaic were used only for WES datasets. The DeepMosaic input
- variants were generated by MuTect2 single mode. (b) The pipeline for unpaired samples. The
- pipeline is similar except that MuTect2 single mode without Strelka2 is used. PM: paired mode,
- 781 SM: single mode.
- 782
- 783






Access Ac

785 Extended Data Fig. 2 Mutational signature analysis through Mutalisk shows cell-division-786 related clock-like signatures in the MCD cohort. SBS5 (39.1%) and SBS1 (33%) are clock-

like mutational signatures. SBS1 especially correlates with cell-division and mitosis of stem 787 cells.


- 788
- 789
- 790



791
 792 Extended Data Fig. 3 The locations of the selected MCD variants. (a) The location of two
 793 recurrent variant calls are at the same position between coiled-coil domain (CC) and the first

- 794 SAM domain (S) of Liprin-α4. (b) Two different variants in SERCA1. p.R524C mutation is at
- the nucleotide ATP-binding (N) domain, whereas the pA846T variant is in the 7th
- transmembrane (M7) domain. A: Actuator domain, P: Phosphorylation domain, M:
- 797 Transmembrane domain. (c) Left: The location of p.H226R variant in RAGA protein. GTPase:
- 798 GTPase domain, CRD: C-terminal roadblock domain. Right: UCSC genome browser screenshot

- describing that p.H226 is conserved site across all vertebrates. (d) The location of p.R38Q
- variant in the N-terminal region before BTB (Broad-Complex, Tramtrack and Bric a brac)
- domain of KLHL22. (e) A variant in the S1 domain of NR2C. S1 and S2 together make ligand-
- binding domain (LBD), the target of glutamate. ATD: Amino terminal domain.






805 Extended Data Fig. 4 The ClueGO analysis using the MCD genes result identifies the

biological processes and molecular pathways. The main cluster is related to TOR signaling,

- 807 regulation of cell-matrix adhesion, regulation of focal adhesion assembly, artery morphogenesis.
- 808 Notably, there are also isolated clusters which were not covered in previous studies, for example,
- 809 cardiac muscle cell contraction, calcium ion import and protein localization to synapse. Term p-
- value with Bonferroni correction was reflected in node size (Large: p < 0.0005, medium: p < 0.0005
- 811 0.05, small: p < 0.1).




813 Extended Data Fig. 5 Cell-type identification by DEGs and known marker gene expression


in the MCD snRNAseq dataset. (a) MCD prefix was used for the clusters that have less than
25 % of control origin. (b) DEG analysis using FindAllMarker function in Seurat v4 package.

Top 10 genes for each cluster were presented. Several notable genes helping to define major cell

- types were labeled at the left side. Note that *FGFR3* and *PDGFRA* are up-regulated in Ast-L1/3
- and U1/2/3, respectively, implying that these genes can be the markers for MCD-dominant
- clusters. (c) Selected markers for major cell types in the human cortex. *CUX1*, *CUX2* for upper
- 820 layer excitatory neuronal markers, SATB2 for layer 4 excitatory neuronal marker, *RORB*,
- 821 *FEZF2*, *BCL11B*, *FOXP2*, *ROBO2* for deep layer specific markers, *GAD1*, *GAD2*, *DLX6*, *RELN*
- for inhibitory neuronal markers, GFAP, SLC1A2, SLC1A3, MMD2 for astrocyte markers, PTPRC
- for microglial marker, *OLIG1*, *OLIG2*, *MOBP*, *PLP1* for oligodendrocyte markers, *FGFR1*,
- *FGFR2, FGFR3, PDGFRB, EGFR* for the selected GBM-enriched genes covering subsets of
- 825 MCD-enriched clusters.
- 826



- 827
- Extended Data Fig. 6 The validation of snRNAseq result from HME-6593 shows MCD
 dominant clusters are highly correlate with dysplastic cells in MCD. (a) H&E staining (left)
 and RNAscope (right) staining results with several MCD-dominant markers (*FGFR2, FGFR1, EGFR*) in the same formaldehyde-embedded-paraffin-fixed section. (b) H&E and RNAscope
 result with another section with different RNA probes (*FGFR3* and *PDGFRA*) enriched in MCD
 clusters. Dashed lines indicate blood vessels. White/black arrows are pointing to the dysplastic
- cells.



835

836 Extended Data Fig. 7 Expression patterns of individual MCD genes in the MCD snRNAseq

dataset. The gene members of each eigen module shown in Fig. 6d were colored according to
the name of a given eigengene.

840 Focal Cortical Dysplasia Neurogenetics Consortium (Additional Members)

- 841
- 842 Dr. Yasemin Alanay, Division of Pediatric Genetics, Acibadem Hospital, Istanbul, Turkey
- 843 Dr. Seema Kapoor, Division of Genetics, Genetic & Metabolic Lab, Lok Nayak Hospital &
- 844 Maualana Azad Medical Center, Pakistan
- 845 Dr. Georgia Ramantani, Dr. Thomas Feuerstein, Albert-Ludwigs University, Freiburg, Germany
- 846 Dr. Ingmar Blumcke, Dr. Robyn Busch, Dr. Zhong Ying, Department of Neuropathology,
- 847 University Hopsital Erlangen, Germany
- 848 Dr. Vadym Biloshytsky, Dr. Kostiantyn Kostiuk, Dr. Eugene Pedachenko, A. Romodanov
- 849 Institute of Neurosurgery, Kyiv, Ukraine
- 850 Dr. Marilyn Jones, Diane Masser-Frye, Rady Children's Hospital, San Diego, CA
- 851 Dr. St éphanie Baulac, Dr. Sara Baldassari, Sorbonne University, Paris Brain Institute (ICM),
- 852 Inserm, CNRS, AP-HP, Piti & Salp & ri ère Hospital, Paris, France

853 Dr. Ingo Helbig, Dr. Benjamin C. Kennedy, Division of Neurology, Children's Hospital

- 854 Philadelphia, PA
- 855 Dr. Judy Liu, Dr. Felix Chan, Department of Molecular Biology, ell Biology, and Biochemistry,
- 856 Department of Neurology, Brown University, RI
- 857 Dr. Darcy Krueger, Department of Clinical Pediatrics and Neurology, Cincinnati Children's
- 858 Hospital, OH
- 859 Dr. Richard Frye, Dr. Angus Wilfong, Dr. David Adelson, Barrow Neurological Institute at
- 860 Phoenix Children's Hospital, U Arizona College of Medicine, Phoenix, AZ
- 861 Dr. William Gaillard, Dr. Chima Oluigbo, Children's National Hospital, Washington DC
- 862 Dr. Anne Anderson, Dept of Pediatrics, Baylor College of Medicine, Texas Children's Hospital,
- 863 Houston, TX
- 864
- 865 <u>gmathern@ucla.edu, jwchang@mednet.ucla.edu, renzo.guerrini@meyer.it, yalanay@gmail.com,</u>
- 866 <u>drseemakapoor@gmail.com</u>, <u>Thomas.feuerstein@uniklinik-freiburg.de</u>,
- 867 georgia.ramantani@kispi.uzh.ch, hipo0207@yuhs.ac, carola.haas@uniklinik-freiburg.de,
- 868 <u>catharina.donkels@uniklinik-freiburg.de, takahashi-ped@umin.ac.jp, hrmachad@gmail.com,</u>
- 869 <u>camila.neurociencias@gmail.com, wilsonjr@usp.br, gurnettc@neuro.wustl.edu,</u>
- 870 gardnerc@wustl.edu", ingmar.bluemcke@uk-erlangen.de, vabil@i.ua, ssattar@health.ucsd.edu,
- 871 dgonda@rchsd.org, mnespeca@rchsd.org, mjone@rchsd.org, dmasser-frye@rchsd.org,
- 872 roberthhchen3@gmail.com, jinwu.tsai@gmail.com, stephanie.baulac@sorbonne-universite.fr,
- 873 sara.baldassari@icm-institute.org, HELBIGI@chop.edu, KENNEDYBC@chop.edu,
- 874 judy_liu@brown.edu, felix_chan@brown.edu, darcy.kreuger@cchmc.org,
- 875 rfrye@phoenixchildrens.com, awilfong@phoenixchildrens.com,
- 876 <u>dadelson@phoenixchildrens.com</u>, <u>WGAILLAR@childrensnational.org</u>,
- 877 <u>COluigbo@childrensnational.org</u>, <u>annea@bcm.edu</u>,
- 878

879 Brain Somatic Mosaicism Network

- 880 Boston Children's Hospital: Alice Lee, August Yue Huang, Alissa D'Gama, Caroline Dias,
- 881 Christopher A. Walsh, Eduardo Maury, Javier Ganz, Michael Lodato, Michael Miller, Pengpeng
- Li, Rachel Rodin, Rebeca Borges-Monroy, Robert Hill, Sara Bizzotto, Sattar Khoshkhoo, Sonia
- 883 Kim, Zinan Zhou
- 884 Harvard University: Alice Lee, Alison Barton, Alon Galor, Chong Chu, Craig Bohrson, Doga
- 885 Gulhan, Eduardo Maury, Elaine Lim, Euncheon Lim, Giorgio Melloni, Isidro Cortes, Jake Lee,
- Joe Luquette, Lixing Yang, Maxwell Sherman, Michael Coulter, Minseok Kwon, Peter J. Park,
- 887 Rebeca Borges-Monroy, Semin Lee, Sonia Kim, Soo Lee, Vinary Viswanadham, Yanmei Dou
- Icahn School of Medicine at Mt. Sinai: Andrew J. Chess, Attila Jones, Chaggai Rosenbluh,
 Schahram Akbarian
- 890 Kennedy Krieger Institute: Ben Langmead, Jeremy Thorpe, Sean Cho
- 891 Lieber Institute for Brain Development: Andrew Jaffe, Apua Paquola, Daniel Weinberger,
- 892 Jennifer Erwin, Jooheon Shin, Michael McConnell, Richard Straub, Rujuta Narurkar
- 893 Mayo Clinic: Alexej Abyzov, Taejeong Bae, Yeongjun Jang, Yifan Wang
- 894 NIMH: Anjene Addington, Geetha Senthil
- 895 Sage Bionetworks: Cindy Molitor, Mette Peters
- 896 Salk Institute for Biological Studies: Fred H. Gage, Meiyan Wang, Patrick Reed, Sara Linker
- 897 Stanford University: Alexander Urban, Bo Zhou, Reenal Pattni, Xiaowei Zhu
- 898 Universitat Pompeu Fabra: Aitor Serres Amero, David Juan, Inna Povolotskaya, Irene Lobon,
- 899 Manuel Solis Moruno, Raquel Garcia Perez, Tomas Marques-Bonet
- 900 University of Barcelona: Eduardo Soriano
- 901 University of California, Los Angeles: Gary Mathern
- 902 University of California, San Diego: Danny Antaki, Dan Averbuj, Eric Courchesne, Joseph G.
 903 Gleeson, Laurel L. Ball, Martin W. Breuss, Subhojit Roy, Xiaoxu Yang, Changuk Chung
- 904 University of Michigan: Chen Sun, Diane A. Flasch, Trenton J. Frisbie Trenton, Huira C.
- Kopera, Jeffrey M. Kidd, John B. Moldovan, John V. Moran, Kenneth Y. Kwan, Ryan E. Mills,
 Sarah B. Emery, Weichen Zhou, Xuefang Zhao
- 907 University of Virginia: Aakrosh Ratan
- Yale University: Adriana Cherskov, Alexandre Jourdon, Flora M. Vaccarino, Liana Fasching,
 Nenad Sestan, Sirisha Pochareddy, Soraya Scuder

910

- 911 Christopher.Walsh@childrens.harvard.edu, peter_park@hms.harvard.edu,
- 912 nenad.sestan@yale.edu, gage@salk.edu, drweinberger@libd.org, moranj@umich.edu,
- 913 flora.vaccarino@yale.edu, abyzov.alexej@mayo.edu, jogleeson@health.ucsd.edu,
- 914 gmathern@ucla.edu, ecourchesne1949@gmail.com, s1roy@ucsd.edu, andrew.chess@mssm.edu,
- 915 <u>schahram.akbarian@mssm.edu, pevsner@kennedykrieger.org, mette.peters@sagebase.org</u>,
- 916 <u>cindy.molitor@sagebase.org</u>,
- 917

918 **References**

- Leventer, R.J., Guerrini, R. & Dobyns, W.B. Malformations of cortical development and epilepsy. *Dialogues Clin Neurosci* 10, 47-62 (2008).
- Barkovich, A.J., Dobyns, W.B. & Guerrini, R. Malformations of cortical development and epilepsy. *Cold Spring Harb Perspect Med* 5, a022392 (2015).
- Blumcke, I. *et al.* The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification
 proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. *Epilepsia* 52, 158-74 (2011).
- 925 4. Choi, S.A. & Kim, K.J. The Surgical and Cognitive Outcomes of Focal Cortical Dysplasia. J Korean Neurosurg Soc 62, 321-327 (2019).
- 927 5. Poduri, A. *et al.* Somatic activation of AKT3 causes hemispheric developmental brain malformations. *Neuron*928 74, 41-8 (2012).
- 6. Lee, J.H. *et al.* De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. *Nat Genet* 44, 941-5 (2012).
- 931 7. Baldassari, S. *et al.* Dissecting the genetic basis of focal cortical dysplasia: a large cohort study. *Acta Neuropathol* 138, 885-900 (2019).
- 8. Sim, N.S. *et al.* Precise detection of low-level somatic mutation in resected epilepsy brain tissue. *Acta Neuropathol* 138, 901-912 (2019).
- 935 9. Dou, Y. *et al.* Accurate detection of mosaic variants in sequencing data without matched controls. *Nat Biotechnol* 38, 314-319 (2020).
- 937 10. Yang, X. *et al.* DeepMosaic: Control-independent mosaic single nucleotide variant detection using deep convolutional neural networks. *bioRxiv* (2021).
- Huang, A.Y. *et al.* MosaicHunter: accurate detection of postzygotic single-nucleotide mosaicism through
 next-generation sequencing of unpaired, trio, and paired samples. *Nucleic Acids Res* 45, e76 (2017).
- 941 12. Wang, Y. *et al.* Comprehensive identification of somatic nucleotide variants in human brain tissue. *Genome Biol* 22, 92 (2021).
- Breuss, M.W. *et al.* Autism risk in offspring can be assessed through quantification of male sperm mosaicism.
 Nat Med 26, 143-150 (2020).
- Yang, X. *et al.* Developmental and temporal characteristics of clonal sperm mosaicism. *Cell* 184, 4772-4783
 e15 (2021).
- 947 15. Garcia, C.A.B. *et al.* mTOR pathway somatic variants and the molecular pathogenesis of hemimegalencephaly. *Epilepsia Open* 5, 97-106 (2020).
- Pelorosso, C. *et al.* Somatic double-hit in MTOR and RPS6 in hemimegalencephaly with intractable epilepsy.
 Hum Mol Genet 28, 3755-3765 (2019).
- 951 17. Breuss, M.W. *et al.* Somatic mosaicism in the mature brain reveals clonal cellular distributions during cortical development. *Nature* (2022).
- Bae, T. *et al.* Somatic mutations reveal hypermutable brains and are associated with neuropsychiatric disorders. *medRxiv* (2022).
- 955 19. Bozic, I. *et al.* Accumulation of driver and passenger mutations during tumor progression. *Proc Natl Acad* 956 *Sci U S A* 107, 18545-50 (2010).
- 957 20. Alexandrov, L.B. *et al.* The repertoire of mutational signatures in human cancer. *Nature* **578**, 94-101 (2020).
- State 21. Kim, M. & Costello, J. DNA methylation: an epigenetic mark of cellular memory. *Exp Mol Med* 49, e322 (2017).
- 960 22. Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting

961		functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47, D607-D613 (2019).
962	23.	Bedrosian, T.A. et al. Detection of brain somatic variation in epilepsy-associated developmental lesions.
963		medRxiv (2021).
964	24.	Lai, D. et al. Somatic mutation involving diverse genes leads to a spectrum of focal cortical malformations.
965		medRxiv (2021).
966	25.	Tarabeux, J. et al. Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders
967		and schizophrenia. <i>Transl Psychiatry</i> 1 , e55 (2011).
968	26.	Bezprozvanny, I. Calcium signaling and neurodegenerative diseases. <i>Trends Mol Med</i> 15 , 89-100 (2009).
969	27.	Su, M.Y. <i>et al.</i> Hybrid Structure of the RagA/C-Ragulator mTORC1 Activation Complex. <i>Mol Cell</i> 68 , 835-
970		846 e3 (2017).
971	28.	Chen, J. et al. KLHL22 activates amino-acid-dependent mTORC1 signalling to promote tumorigenesis and
972	20.	ageing. Nature 557, 585-589 (2018).
973	29.	Behar, T.N. <i>et al.</i> Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. J
974	2).	Neurosci 19, 4449-61 (1999).
975	30.	Paoletti, P., Bellone, C. & Zhou, Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic
976	50.	plasticity and disease. <i>Nat Rev Neurosci</i> 14, 383-400 (2013).
	21	
977	31.	Strehlow, V. <i>et al.</i> GRIN2A-related disorders: genotype and functional consequence predict phenotype. <i>Brain</i>
978	22	142 , 80-92 (2019).
979	32.	Prickett, T.D. & Samuels, Y. Molecular pathways: dysregulated glutamatergic signaling pathways in cancer.
980		<i>Clin Cancer Res</i> 18 , 4240-6 (2012).
981	33.	Ruvinsky, I. & Meyuhas, O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size.
982		<i>Trends Biochem Sci</i> 31 , 342-8 (2006).
983	34.	Sumimoto, H., Imabayashi, F., Iwata, T. & Kawakami, Y. The BRAF-MAPK signaling pathway is essential
984		for cancer-immune evasion in human melanoma cells. J Exp Med 203, 1651-6 (2006).
985	35.	Ornitz, D.M. & Itoh, N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol 4,
986		215-66 (2015).
987	36.	Chen, X. et al. TNF-alpha-Induced NOD2 and RIP2 Contribute to the Up-Regulation of Cytokines Induced
988		by MDP in Monocytic THP-1 Cells. J Cell Biochem 119, 5072-5081 (2018).
989	37.	Yates, T.M. et al. SLC35A2-related congenital disorder of glycosylation: Defining the phenotype. Eur J
990		Paediatr Neurol 22, 1095-1102 (2018).
991	38.	Paganini, C. et al. Calcium activated nucleotidase 1 (CANT1) is critical for glycosaminoglycan biosynthesis
992		in cartilage and endochondral ossification. Matrix Biol 81, 70-90 (2019).
993	39.	Lee, N. et al. Neuronal migration disorders: positron emission tomography correlations. Ann Neurol 35, 290-
994		7 (1994).
995	40.	Kim, Y.H. et al. Neuroimaging in identifying focal cortical dysplasia and prognostic factors in pediatric and
996		adolescent epilepsy surgery. Epilepsia 52, 722-7 (2011).
997	41.	Nowakowski, T.J. et al. Spatiotemporal gene expression trajectories reveal developmental hierarchies of the
998		human cortex. Science 358 , 1318-1323 (2017).
999	42.	Coe, B.P. et al. Neurodevelopmental disease genes implicated by de novo mutation and copy number
1000		variation morbidity. <i>Nat Genet</i> 51 , 106-116 (2019).
1001	43.	Ridley, A.J. <i>et al.</i> Cell migration: integrating signals from front to back. <i>Science</i> 302 , 1704-9 (2003).
1002	44.	Brini, M., Cali, T., Ottolini, D. & Carafoli, E. Neuronal calcium signaling: function and dysfunction. <i>Cell</i>
1003		Mol Life Sci 71 , 2787-814 (2014).
1003	45.	Lamparello, P. <i>et al.</i> Developmental lineage of cell types in cortical dysplasia with balloon cells. <i>Brain</i> 130 ,
1005	ч	2267-76 (2007).
1005	46.	Englund, C., Folkerth, R.D., Born, D., Lacy, J.M. & Hevner, R.F. Aberrant neuronal-glial differentiation in
1000	40.	Taylor-type focal cortical dysplasia (type IIA/B). <i>Acta Neuropathol</i> 109 , 519-33 (2005).
1007	17	Kim, S. <i>et al.</i> Strelka2: fast and accurate calling of germline and somatic variants. <i>Nat Methods</i> 15 , 591-594
	47.	
1009	40	
1010	48.	Benjamin, D. <i>et al.</i> Calling Somatic SNVs and Indels with Mutect2. <i>bioRxiv</i> (2019).
1011	49.	Yang, X. <i>et al.</i> Genomic mosaicism in paternal sperm and multiple parental tissues in a Dravet syndrome
1012	50	cohort. <i>Sci Rep</i> 7 , 15677 (2017).
1013	50.	Untergasser, A. et al. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 35, W71-4
1014		(2007).

- 1015 51. Untergasser, A. et al. Primer3--new capabilities and interfaces. Nucleic Acids Res 40, e115 (2012).
- 1016 52. Lee, J. *et al.* Mutalisk: a web-based somatic MUTation AnaLyIS toolKit for genomic, transcriptional and epigenomic signatures. *Nucleic Acids Res* **46**, W102-W108 (2018).
- 1018 53. Bindea, G. *et al.* ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* **25**, 1091-3 (2009).
- 1020 54. Koizumi, H., Tanaka, T. & Gleeson, J.G. Doublecortin-like kinase functions with doublecortin to mediate fiber tract decussation and neuronal migration. *Neuron* 49, 55-66 (2006).
- 1022 55. Wang, F. *et al.* RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. *J Mol Diagn* **14**, 22-9 (2012).